Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

158.38 +3.72 (+2.41%)
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,342,903
Open 156.44
Bid (Size) 158.38 (5)
Ask (Size) 158.50 (3)
Prev. Close 154.66
Today's Range 155.47 - 158.46
52wk Range 144.95 - 181.04
Shares Outstanding 2,628,679,824
Dividend Yield 3.01%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Warren Buffett Just Closed His Position in This Dividend Giant. Should You?
J&J has a long track record of dividend growth -- something Buffett generally appreciates. 
Via The Motley Fool
Barron's Weekend Stock Picks: Uber Joins The S&P 500, Schwab Rebounds And What's Next for Johnson & Johnson?
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Topics Stocks
Exposures US Equities

Performance

YTD
-11.12%
-11.12%
1 Month
+5.42%
+5.42%
3 Month
-1.43%
-1.43%
6 Month
+0.04%
+0.04%
1 Year
-11.46%
-11.46%

More News

Read More
Johnson & Johnson Gets Analyst Upgrade Noting Bullish Pharma & MedTech Projections
Via Benzinga
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Investors Should Not Pay More Than A 15 P/E Ratio When Buying A Stock
Via Talk Markets
This Is What Whales Are Betting On Johnson & Johnson
Via Benzinga
Is NYSE:JNJ suited for dividend investing?
Via Chartmill
Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio
Via InvestorPlace
Warren Buffett Reduced This Long-Time Berkshire Hathaway Holding by 67%. Should Investors Follow His Lead?
Via The Motley Fool
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors
From Johnson & Johnson
Via Business Wire
7 Blue-Chip Stocks to Buy for 2024, According to AI
Via InvestorPlace
Income Kings: 7 Blue-Chip Dividend Stocks for Reliable Returns
Via InvestorPlace
Fresh on the Market: 3 Top Picks From the Renaissance IPO ETF
Via InvestorPlace
Topics ETFs Initial Public Offering
Exposures Securities Market
Johnson & Johnson MedTech Acquires Laminar, Inc.
From Johnson & Johnson MedTech
Via Business Wire
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Via Benzinga
Exposures Product Safety
The 7 Biggest Dividend Stocks in Warren Buffett’s Portfolio
Via InvestorPlace
J&J, Gilead, BMS: A look at undervalued dividend payers
Via MarketBeat
2023's most anticipated IPOs weren't always the big winners
Via MarketBeat
Topics ETFs Initial Public Offering Stocks
Exposures Securities Market US Equities
Daily Wear Contact Lenses Market May See a Big Move: Major Giants Alcon, Hydron, Lagado Corporation, Metro Optics, Johnson & Johnson Vision Care
Via SBWire
Teva Pharma is the way to play the re-rise of generic drugs
Via MarketBeat
2 Unstoppable Dividend Stocks Trading Near 52-Week Lows to Buy Now
Via The Motley Fool
Google Alum's Biotech Startup Cradle Raises $24M To Boost AI-Powered Protein Design And Engineering
Via Benzinga
3 Robotics Stocks That Could Be Multibaggers in the Making
Via InvestorPlace
The Shocking Stock That Warren Buffet Just Bought (and 2 He Sold)
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.